Page last updated: 2024-10-15

alanosine

Cross-References

ID SourceID
PubMed CID135409347
CHEMBL ID452715
SCHEMBL ID17445
MeSH IDM0040086

Synonyms (45)

Synonym
alanosine
nsc-529469
2-amino-3-(hydroxynitrosamino)propionic acid, l-
l-alanine, 3-(hydroxynitrosoamino)-
l-2-amino-3-(hydroxynitrosamino)propionic acid
NCIMECH_000737
alanosine (van)
ai3-52867
nsc 153353
propionic acid, 2-amino-3-(hydroxynitrosamino)-, (l)-
l-2-amino-3-((n-nitroso)hydroxylamino)propionic acid
3-(hydroxynitrosoamino)-l-alanine
(-)-(s)-2-amino-3-(hydroxynitrosamino)propionsaeure
(-)-(s)-2-amino-3-(hydroxynitrosamino)propionic acid
brn 2046850
alanosinum [latin]
alanosina [spanish]
l-2-amino-3-(n-nitroso)hydroxylaminopropionic acid
alanosine [inn]
l-alanine, 3-(hydroxynitrosoamino)
5854-93-3
(2s)-2-amino-3-[hydroxy(nitroso)amino]propanoic acid
l-alanosine
alanosine, (*monosodium salt*)
nsc-153353
sdx-102
CHEMBL452715
3-(hydroxynitrosoamino)alanine
AKOS006273974
2cni71214y ,
alanosinum
alanosina
unii-2cni71214y
CCG-35846
16931-22-9
l-alanosine [mi]
alanosine [mart.]
SCHEMBL17445
HY-16933
DB05540
dl-alanosine; ent 52867; nsc 143647
CS-0012981
MS-22842
(z)-[(2s)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium
DTXSID501024175

Research Excerpts

Overview

L-alanosine (NSC 15353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism. Alanosine is an amino acid analog originally derived from Streptomyces alanosinicus.

ExcerptReference
"l-Alanosine is a diazeniumdiolate ("( Reductases Produce Nitric Oxide in an Alternative Pathway to Form the Diazeniumdiolate Group of l-Alanosine.
Ryan, KS; Wang, M, 2023
)
"L-alanosine is an antitumor compound which has recently entered clinical trials. "( Effect of L-alanosine on immune response.
Bassi, L; Mistrello, G, 1984
)
"L-alanosine (NSC 15353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism. "( Phase I study of L-alanosine (NSC 15353).
Goldsmith, MA; Greenspan, EM; Holland, JF; Ohnuma, T; Spigelman, M, 1983
)
"L-Alanosine is an antitumor antibiotic that inhibits adenine synthesis. "( Phase I study of L-alanosine using a daily x 3 schedule.
Bodey, GP; Burgess, MA; Dosik, GM; Stewart, D; Valdivieso, M, 1982
)
"Alanosine is an amino acid analog originally derived from Streptomyces alanosinicus."( Alanosine (UCSD).
Yu, J, 2001
)
"L-Alanosine is an antitumour antibiotic that has recently been placed in clinical trial. "( Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative.
Ames, MM; Powis, G, 1979
)

Treatment

ExcerptReference
"Alanosine treatment results in the inhibition of cell division, DNA synthesis, RNA and protein synthesis (in this order), and a depletion of the cells of adenosine triphosphate."( Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate.
Graff, JC; Plagemann, PG, 1976
)

Toxicity

ExcerptReference
" Dose-dependent metabolism of methotrexate is unusual in that formation of the presumed toxic metabolite increases with increase in dose and is associated with a qualitative change in the pattern of drug toxicity at high compared to low doses of drug."( Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Powis, G, 1983
)
" The LD50 of L-alanosine (given intraperitoneally) was approximately 2 g/kg; L-5178Y/AR tumor, small intestine, liver, and lung were the tissues more consistently or severely damaged by the drug."( Determinants of the toxicity of L-alanosine to various organs of the mouse.
Cooney, DA; McGee, E; Thake, DC; Tyagi, AK, 1981
)

Dosage Studied

ExcerptReference
" Therapeutic response to both drugs has been linked to plasma concentration of parent compound, and a nonlinear dose-response relationships might exist at high doses."( Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Powis, G, 1983
)
" The relevance of circadian dosing time was investigated for chronotherapeutic optimization of SDX-102."( Circadian pharmacology of L-alanosine (SDX-102) in mice.
Carrière, J; Crépin, D; Elliott, G; Guettier, C; Kanekal, S; Lévi, F; Li, XM, 2006
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (57.14)18.7374
1990's14 (18.18)18.2507
2000's13 (16.88)29.6817
2010's3 (3.90)24.3611
2020's3 (3.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.13%)5.53%
Reviews5 (6.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other69 (88.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer[NCT00062283]Phase 20 participants Interventional2003-03-31Completed
A Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study Of Intravenous SDX-102 For The Treatment Of Patients With MTAP-Deficient High Grade Recurrent Malignant Gliomas[NCT00075894]Phase 118 participants (Anticipated)Interventional2004-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]